Skip to main content
European Commission logo print header

Article Category


Article available in the following languages:


European Technology Platform for Nanomedicine and the ENATRANS consortium launch second edition of the Nanomedicine Award

The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium ENATRANS have launched the second edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2015. The Award will be presented at the BIO-Europe conference in Munich in November 2015. Apply at

The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients. The Award is open to companies as well as academic and private researchers across the globe. Nominated projects should be totally new diagnostic and therapeutic approaches that address unmet medical needs with nanomedicine, and have an explicit and defined potential market. Nanomedicine proposals will be evaluated in two categories: - Best early clinical stage project Award - Best product or deal Award Applications will be reviewed and assessed by a panel of highly-qualified industry experts with experience in R&D and business roles: - Patrick Boisseau, Business Development Nanomedicine at CEA-Leti and President of the ETPN - Patrick Tricoli, VP Corporate Development and CEO Nanobiotix Corp. - Jeff Hrkach, formerly Chief Technology Officer of BIND Therapeutics, Inc. and member of the Nanomedicines Alliance - Henry Havel, formerly Senior Research Fellow at Eli Lilly and Chairman of the Nanomedicines Alliance For the first time in its history, the ETPN gets together with the US-based Nanomedicines Alliance for a meaningful initiative. The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, the Nanomedicines Alliance, the US-based consortium dedicated to promoting and facilitating the scientific advancement, regulatory approval, and public appreciation of nanotechnology‐based medicines and Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Award ceremony will take place during BIO-Europe 2015 in Munich, Germany, on November the 3rd, 2015. Winners will benefit from a full registration (including partnering) for BIO-Europe 2015 and a 10 minute project presentation during the Conference. The winning projects will also be granted with a presentation during the ETPN General Assembly 2016, along with 1 year’s free ETPN membership and a consulting action by the experts from the Translation Advisory Board (TAB). The winners will gain visibility to EU decision makers from pharma industry, academia, finance and media. Applications for the Award are open until 15 September, 2015. The application form is available online at About ETPN: www.etp‐ Created in 2005, the European Technology Platform for Nanomedicine is an initiative led by Industry and set up together with the European Commission to address the applications of nanotechnology to achieve breakthroughs in healthcare. The ETPN is structuring and federating the European Nanomedicine community and leading the communication toward the European Commission and the European Members States. About ENATRANS: Enabling NAnomedicine TRANSlation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to Nanomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on Nanomedicine. About BIOEUROPE 2015: The 21st annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,200 international decision makers from biotech, pharma and finance along with the most promising start-ups and emerging companies, representing upwards of 1,800 companies, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place 2-4 November, 2015 in Munich, Germany.


nanomedicine, nanotechnology, Health, medicine, diagnostic, therapies, clinical stage, products, BIO


Germany, France, United States